[go: up one dir, main page]

EP3603636A4 - S1PR4 COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS - Google Patents

S1PR4 COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS Download PDF

Info

Publication number
EP3603636A4
EP3603636A4 EP18774760.5A EP18774760A EP3603636A4 EP 3603636 A4 EP3603636 A4 EP 3603636A4 EP 18774760 A EP18774760 A EP 18774760A EP 3603636 A4 EP3603636 A4 EP 3603636A4
Authority
EP
European Patent Office
Prior art keywords
s1pr4
prevention
treatment
composition
alcoholic steatohepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18774760.5A
Other languages
German (de)
French (fr)
Other versions
EP3603636A1 (en
Inventor
Eun Hee Koh
Ki Up Lee
Sang Hee Kim
Dae Duk Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asan Foundation
University of Ulsan Foundation for Industry Cooperation
SNU R&DB Foundation
Original Assignee
Asan Foundation
University of Ulsan Foundation for Industry Cooperation
SNU R&DB Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asan Foundation, University of Ulsan Foundation for Industry Cooperation, SNU R&DB Foundation filed Critical Asan Foundation
Publication of EP3603636A1 publication Critical patent/EP3603636A1/en
Publication of EP3603636A4 publication Critical patent/EP3603636A4/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP18774760.5A 2017-03-29 2018-03-29 S1PR4 COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS Pending EP3603636A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170040139A KR102292989B1 (en) 2017-03-29 2017-03-29 Composition for preventing and treating nonalcoholic steatohepatitis by targeting S1PR4
PCT/KR2018/003711 WO2018182329A1 (en) 2017-03-29 2018-03-29 S1pr4-targeting composition for preventing or treating non-alcoholic steatohepatitis

Publications (2)

Publication Number Publication Date
EP3603636A1 EP3603636A1 (en) 2020-02-05
EP3603636A4 true EP3603636A4 (en) 2020-12-30

Family

ID=63677916

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18774760.5A Pending EP3603636A4 (en) 2017-03-29 2018-03-29 S1PR4 COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS

Country Status (11)

Country Link
US (1) US11571435B2 (en)
EP (1) EP3603636A4 (en)
JP (1) JP6890805B2 (en)
KR (1) KR102292989B1 (en)
CN (1) CN110475554B (en)
AU (2) AU2018246796B2 (en)
BR (1) BR112019020262A2 (en)
CA (1) CA3058124C (en)
MX (1) MX2019011795A (en)
SA (1) SA519410204B1 (en)
WO (1) WO2018182329A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102292989B1 (en) 2017-03-29 2021-08-26 재단법인 아산사회복지재단 Composition for preventing and treating nonalcoholic steatohepatitis by targeting S1PR4
KR102105880B1 (en) * 2018-10-26 2020-04-29 서울대학교병원 Methods for providing information about the diagnosis of histologic severity or prognostic measurement of nonalcoholic fatty liver disease
KR102540720B1 (en) * 2020-02-18 2023-06-08 재단법인 아산사회복지재단 Pharmaceutical Composition for preventing or treating asthma or bronchitis
KR102752714B1 (en) * 2020-09-22 2025-01-10 경북대학교 산학협력단 Use of triazol compounds as ghrelin receptor agonists
KR102563719B1 (en) * 2021-09-15 2023-08-04 주식회사 넥스트젠바이오사이언스 Pharmaceutical composition for preventing or treating IFTA acting as a functional inhibitor for S1PR1 and S1PR4
KR102541579B1 (en) * 2021-09-15 2023-06-13 주식회사 넥스트젠바이오사이언스 Pharmaceutical composition for preventing or treating focal segmental glomerulosclerosis acting as a functional inhibitor for S1PR1 and S1PR4
KR102533409B1 (en) 2021-11-04 2023-05-26 주식회사 넥스트젠바이오사이언스 A Novel Salt of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propan-1,3-diol, Preparation Methods thereof and Pharmaceutical Compositions Comprising thereof
KR102541578B1 (en) * 2022-03-23 2023-06-13 주식회사 넥스트젠바이오사이언스 Pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional inhibitor for S1PR1 and S1PR4
KR20230161357A (en) * 2022-05-18 2023-11-27 주식회사 넥스트젠바이오사이언스 Pharmaceutical composition for preventing and treating radiation induced pulmonary fibrosis acting as a functional inhibitor for S1PR1 and S1PR4
CA3213748A1 (en) * 2022-10-21 2023-12-08 Bongyong Lee Pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for s1pr1 and s1pr4
KR102541577B1 (en) * 2022-10-21 2023-06-13 주식회사 넥스트젠바이오사이언스 Pharmaceutical composition for preventing or treating alopecia areata as a functional antagonist for s1pr1 and s1pr4
WO2024237668A1 (en) * 2023-05-15 2024-11-21 주식회사 넥스트젠바이오사이언스 Method for administering modulator targeting s1pr1 and s1pr4

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096757A1 (en) * 2003-04-30 2004-11-11 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
WO2008064320A2 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
WO2009060053A1 (en) * 2007-11-09 2009-05-14 Smithkline Beecham Corporation 1, 2, 3-triazole derivatives for use as stearoyl-coa desaturase inhibitors
WO2010068775A2 (en) * 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
WO2014145873A2 (en) * 2013-03-15 2014-09-18 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9738613B2 (en) 2015-05-18 2017-08-22 National Central University Substituted 1,2,3-triazoles as antitumor agents
KR20170025909A (en) 2015-08-31 2017-03-08 가천대학교 산학협력단 Pharmaceutical composition for preventing or treating metabolic dysfunction comprising sphingosine 1-phosphate or a Sphk2 expression-elevating agent
KR102292989B1 (en) 2017-03-29 2021-08-26 재단법인 아산사회복지재단 Composition for preventing and treating nonalcoholic steatohepatitis by targeting S1PR4

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096757A1 (en) * 2003-04-30 2004-11-11 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
WO2008064320A2 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
WO2009060053A1 (en) * 2007-11-09 2009-05-14 Smithkline Beecham Corporation 1, 2, 3-triazole derivatives for use as stearoyl-coa desaturase inhibitors
WO2010068775A2 (en) * 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
WO2014145873A2 (en) * 2013-03-15 2014-09-18 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMY S. MAUER ET AL: "Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis", AMERICAN JOURNAL OF PHYSIOLOGY - GASTROINTESTINAL AND LIVER PHYSIOLOGY, vol. 312, no. 3, 30 December 2016 (2016-12-30), US, pages G300 - G313, XP055612529, ISSN: 0193-1857, DOI: 10.1152/ajpgi.00222.2016 *
YULIN TIAN ET AL: "Discovery of oxazole and triazole derivatives as potent and selective S1P1 agonists through pharmacophore-guided design", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 85, 24 July 2014 (2014-07-24), NL, pages 1 - 15, XP055612530, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2014.07.081 *

Also Published As

Publication number Publication date
BR112019020262A2 (en) 2020-04-22
JP2020512369A (en) 2020-04-23
US20210100820A1 (en) 2021-04-08
KR102292989B1 (en) 2021-08-26
AU2018246796B2 (en) 2021-04-01
CA3058124C (en) 2022-07-05
US11571435B2 (en) 2023-02-07
MX2019011795A (en) 2020-01-27
WO2018182329A1 (en) 2018-10-04
KR20180110499A (en) 2018-10-10
EP3603636A1 (en) 2020-02-05
AU2021202271A1 (en) 2021-05-06
CN110475554A (en) 2019-11-19
JP6890805B2 (en) 2021-06-18
CN110475554B (en) 2022-12-30
CA3058124A1 (en) 2018-10-04
SA519410204B1 (en) 2022-09-01
AU2018246796A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
EP3603636A4 (en) S1PR4 COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
EP3263132C0 (en) COMPOSITION FOR THE TREATMENT OF IL-6-ASSOCIATED DISEASES
EP3498297C0 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM
EP3581185A4 (en) URSODEOXYCHOLIC ACID COMPOSITION FOR THE PREVENTION OR TREATMENT OF VISUAL DISORDERS
IL272121A (en) Composition and methods for the treatment of myopia
EP3655036C0 (en) COMPOSITIONS FOR THE TREATMENT OF STRESS-RELATED DISORDERS
EP3569238A4 (en) COMPOSITION FOR THE TREATMENT OF NEONATAL HIE
EP3398437A4 (en) METCONA-COOKED PESTICIDE COMPOSITION FOR THE PREVENTION AND TREATMENT OF EARLY FUSARIOS AND USE THEREOF
EP3573620A4 (en) COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION
EP3493823C0 (en) POSTBIOTICS-BASED COMPOSITION FOR THE TREATMENT OF EYE INFECTIONS
EP3283115C0 (en) COMPOSITIONS FOR THE TREATMENT OF AUTISM
EP3801478A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF CALCIPHYLAXIA
EP3691632C0 (en) COMPOSITIONS, METHODS, SYSTEMS AND/OR KITS FOR THE PREVENTION AND/OR TREATMENT OF NEOPLASMAS
EP3556402A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS B
EP3719032A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF HAIR LOSS
EP3817749A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
EP3533471A4 (en) COMPOSITION FOR THE REDUCTION OR TREATMENT OF PAIN
EP3634394A4 (en) COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP3638304A4 (en) CICAVIRUS STRAINS FOR TREATMENT OF GLIOBLASTOMES
EP3804728A4 (en) COMPOSITION WITH INOTODIOL COMPOUND AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF ALLERGY DISEASES
EP3612133A4 (en) IMPLANTABLE SCAFFOLDING FOR THE TREATMENT OF SINUSITIS
EP3777848C0 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF STROKE
EP3610879A4 (en) COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF ALZHEIMER'S DISEASE
IT201700121764A1 (en) Composition for the treatment and / or prevention of neurodegenerative diseases.
EP3755336A4 (en) COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF UVEITIS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190927

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20201202

RIC1 Information provided on ipc code assigned before grant

Ipc: A23L 33/10 20160101ALI20201126BHEP

Ipc: A61K 45/06 20060101ALI20201126BHEP

Ipc: A61K 31/4192 20060101ALI20201126BHEP

Ipc: A61K 31/42 20060101AFI20201126BHEP

Ipc: A61K 31/66 20060101ALI20201126BHEP

Ipc: A61P 1/16 20060101ALI20201126BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231115